🔗 Share this article

A shadow economy for unlicensed slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Experimental Treatment Gaining Popularity Via Social Media

The experimental drug, which remains in clinical trials, is being promoted by online personalities for its supposed weight-reducing effects. Viewers are encouraged to contact these accounts privately for supplier links, while also obtaining promotional offers.

Thriving Trade on Social Networks

Separately, a robust market exists on messaging services, where communities with thousands of members share “before and after” photos, injection guides and claims of rapid British shipping. Vendors promote the drug there before redirecting buyers to other platforms for transactions.

Understanding Retatrutide

Retatrutide is an experimental injection developed by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist individuals reduce up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being hailed online as the successor to Ozempic.

Healthcare Experts Voice Worries

However, physicians and chemists have cautions that the sale of what is still an unapproved medication in the UK is a cause for concern and could result in individuals administering substances of uncertain source.

Several professionals said the demand for the experimental drug could be linked to the increasing cost of licensed slimming products such as Mounjaro.

Legal Status and Implementation

Marketing the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unlicensed medication that must not be marketed or distributed for human use under the Human Medicines Regulations 2012.

Several influencers try to circumvent the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still breach pharmaceutical, advertising, and customer laws, potentially leading to penalties, legal action or imprisonment.

Service Reaction and Content Elimination

Based on the social media company, the platform has removed problematic content and prohibited associated keywords and search suggestions. The organization said it was committed to maintaining the service secure and investing in enhancing compliance measures.

Online Marketplace Activities

Research also found communities with up to nine thousand participants marketing retatrutide using the platform's built-in discovery tool, which functions like a public directory. Typing “retatrutide” immediately brings up channels with thousands of users, populated with images of slimming results, glowing testimonials and step-by-step instructions for preparing or administering at home.

Within moments of entering one group, a vendor posted WhatsApp details, where the majority of purchases occur. The seller sent an instruction manual and promised delivery within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one asked about weight, medical conditions or past usage.

Item Information and Pricing

Inside these communities, posts show black plastic parcels with postal service labels, stating to include new batches. One message stated: “It took eight of us to load them this morning.”

Customers can choose between powder vials, prepared at home with purified liquid, or pre-filled pens typically priced at 160 pounds for 20 milligrams. When questioned how long a injector should last, vendors give conflicting answers ranging from a several days to “depends on your body”.

Platform Moderation and Security Actions

A representative for the messaging service said it regularly moderated harmful material on its platform including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are injecting substances they cannot confirm. Although the science behind this drug is sound, these digital versions may not contain what they claim,” said Jason Murphy, the director of pharmacy at Chemist4U.

A medical professional of an online medical service linked the increase in demand to recent cost increases for approved weight-loss drugs such as Mounjaro. “With prices rising, patients are turning to social media. But fake treatments are extremely risky. You cannot know what’s inside or whether the conditions they were made in was sterile,” she said.

Her team has already seen individuals harmed by self-injection from unconfirmed sources. “We recognize the disappointment, but purchasing from Telegram or WhatsApp is gambling with your well-being,” stated Wyllie. “These substances could be contaminated or incorrectly dosed.”

Producer Statement

A representative from the pharmaceutical company said retatrutide was in third stage research studies and had not been evaluated or authorized by any government authority globally. “Therefore at this time no one can sell [it] for human use,” they explained, adding that any item “falsely representing itself as a Lilly investigational substance not yet approved … may expose patients to potentially significant medical dangers”.